Skip to content
Contact
About PORTAL
Our Team
Our Work
Innovation Incentives and Competition
Regulation and Clinical Evidence
Price, Value, and Access
Search Our Library
The Double-Edged Sword of Extremely High Prices for Gene Therapies in Sickle Cell Disease
HOME
/
Commentary & Opinion
/
The Double-Edged Sword of Extremely High Prices for Gene Therapies in Sickle Cell Disease